Key Highlights
● Second-quarter 2026 net sales were $629,312, down from $697,925 a year earlier, and the net loss was $292,358.
● At 30 June 2026 cash was $246,772 against current liabilities of $11,112,964, a Working Capital Deficit of about $10.5 million.
● The filing states substantial doubt about the company's ability to continue as a going concern, citing an accumulated deficit of about $36.3 million.
● Shares outstanding reached 2,738,521,585 after about 2.035 billion shares were issued on note conversions in the first half, against five billion authorised.
Stemtech Corporation (OTC:STEK) has drawn attention in the consumer health and wellness sector because it is attempting a change of sales model while its latest Quarterly Report describes a very thin financial cushion. Management is trying to widen how customers buy its products, yet the Balance Sheet leaves little room for error.
Net sales fell in the second quarter of 2026 even as the new retail channel opened.
What the Business Does
Stemtech describes itself as the Stem Cell Nutrition Company. Its range includes the RCM System, stemrelease3, StemFlo, MigraStem, OraStem and the Cellect One skincare lines, which it says are intended to support healthy stem cell physiology. The products are sold mainly through network marketing, using independent distributors across North America, Latin America and Asia.
Revenue therefore depends on how many distributors remain active and how much they buy. In 2026 the company has publicly moved towards a hybrid approach. On 26 February 2026 it announced a Shopify-based E-commerce platform for direct consumer sales, and on 18 March 2026 it introduced what it called Stemtech Revolution 2026, combining the existing distributor network with a new retail channel branded Stemtech BioSciences.
Second-Quarter Results
The most recent financial information is the quarterly report for the period ended 30 June 2026. Net sales for the second quarter were $629,312, compared with $697,925 a year earlier. Gross Profit was $465,673, against $552,016, and gross Margin eased to about 74 per cent from about 79 per cent. The net loss for the quarter was $292,358, marginally better than the $296,280 loss recorded in the same quarter of 2025.
For the first half, net sales were $1,092,269, down from $1,565,971, while gross profit fell from $1,272,280 to $819,980. The half-year net loss narrowed to $1,453,418 from $1,755,006, an improvement of roughly $301,600 despite the lower revenue.
Balance Sheet and Financing
At 30 June 2026 Stemtech held cash of $246,772 and total current Assets of $571,233, against current liabilities of $11,112,964. That produced a working capital deficit of about $10.5 million and a stockholders' deficit of $8,216,405. Total assets were $3,163,559.
Liabilities included notes payable of $2,564,020, convertible debentures of $1,832,414 net, a factoring Liability of $792,918 and an inventory financing liability of $188,165. In April 2026 the company entered an inventory financing arrangement of up to $500,000 with an investor, under which the investor receives 4.9 per cent non-dilutable convertible preferred stock and 1,600,000 warrants, with repayment set at a premium to inventory cost that rises the longer funds remain outstanding.
Share count has moved sharply. The company reported 2,738,521,585 shares outstanding at 30 June 2026, after issuing about 277.1 million shares for services and about 2.035 billion shares on conversion of convertible notes during the first half.
Material Risks
The filing states that the conditions it describes raise substantial doubt about the company's ability to continue as a going concern, citing an accumulated deficit of about $36.3 million and the working capital deficiency. Management says it has reduced its workforce and overhead and depends on further Debt and equity financing.
Further conversions of convertible debt would dilute existing holders, authorised shares total five billion, and the Revenue decline shows that the new retail channel has not yet offset weaker distributor demand. Financing on these terms is costly, and limited cash means any funding delay could disrupt inventory purchases.
Net Sales, Share Issuance and the Working Capital Gap
Open questions include whether quarterly net sales stabilise as the e-commerce channel matures, whether gross margin recovers from its recent decline, how many further shares are issued, and whether the working capital deficit is reduced through restructuring or new capital. Stemtech's strategic direction is clearer than its financial footing.



_11_13_2026_19_06_49_317610.jpg)


Please wait processing your request...